Anders, M., Christian, C., McMahon, M., McCormick, F., and Korn, W. M. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Research, 63:2088-2095, 2003.
Argilla, D., Chin, K., Singh, M., Hodgson, J. G., Bosenberg, M., de Solorzano, C. O., Lockett, S., DePinho, R. A., Gray, J., and Hanahan, D. Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes. Cancer Cell, 6:373-85, 2004.
Bagdanani, I., Chan, W., Castro, R., Brett, C., Huang, C., Stryke, D., Kawamoto, M., Johns, S., Ferrin, T., Carlson, E., Burchard, E., and Giacomini, K. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics Journal, 5:157-65, 2005.
Bergers, G., Javaherian, K., Lo, K., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284:808-12, 1999.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 111:1287-95, 2003.
Casanovas, O., Hager, J. H., Chun, M. G., and Hanahan, D. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene, 24:6597-604, 2005.
Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 8:299-309, 2005.
Chan, J. M., Wang, F., and Holly, E. A. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area. Cancer Epidemiology Biomarkers and Prevention, 14:2093-7, 2005.
Christophorou, M., Martin-Zanca, D., Soucek, L. Lawlor, E. R., Brown-Swigart, L., Vershuren, E., and Evan, G. I. Temporal dissection of p53 function in vitro and in vivo. Nature Genetics, 37:718-26, 2005.
Christophorou, M. A., Ringshausen I., Finch A. J., Brown Swigart L. and Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumor suppression. Nature, 443:214-217, 2006.
Cohen, M. B., Egerter, D. P., Holly, E. A., Ahn, D. K., and Miller, T. R. Pancreatic adenocarcinoma: regression analysis to identify improved cytologic criteria. Diagnostic Cytopathology, 7:341-5, 1991.
Crabtree, J., Scacheri, P., Ward, J., McNally, S., Swain, G., Montagna, C., Hager, J., Hanahan, D., Edlund, H., Magnuson, M., Garrett-Beal, L., Burns, A., Ried, T., Chandrasekharappa, S., Marx, S., Spiegel, A., and Collins, F. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Molecular and Cellular Biology, 23:6075-85, 2003.
Cress, R. D., Yin, D., Clarke, L., Bold, R., and Holly, E. A. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes and Control, 17:403-9, 2006.
Dansen, T., Whitfield, J., Rostker, F., Brown-Swigart, L., Evan, G. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. Journal of Biological Chemistry, 281:10890-5, 2006.
Dresser, M., Xiao, G., Leabman, M., Gray, A., and Giacomini, K. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharmacology Research, 19:1244-7, 2002.
Duell, E. J., and Holly, E. A. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. American Journal of Epidemiology, 161:741-7, 2005.
Duell, E. J., Holly, E. A., Bracci, P. M., Liu, M., Wiencke, J. K., and Kelsey, K. T. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. Journal of the National Cancer Institute, 94:297-306, 2002.
Duell, E. J., Holly, E. A., Bracci, P. M., Wiencke, J. K., and Kelsey, K. T. A population-based study of the Arg399Gln polymorphism in X-ray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Research, 62:4630-6, 2002.
Duell, E., Casella, D. P., Burk, R. D., Kelsey, K. T., and Holly, E. A. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 15:726-31, 2006.
Eberle, C. A., Bracci, P. M., and Holly, E. A. Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes and Control, 16:1235-44, 2005.
Finch, A. J., Prescott, J., Shchors, K., Hunt, A., Soucek, L., Dansen, T. D., Brown Swigart, L., and Evan, G. I. Bcl-xL gain of function and ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell, in press, 2006.
Folkman, J., Watson, K., Ingber, D., and Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339:58-61, 1989.
Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D., and Joyce, J. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes and Development, 20:543-56, 2006.
Gray, J., Mangravite, L., Owen, R., Urban, T., Chan, W., Carlson, E., Huang, C., Kawamoto, M., Johns, S., Stryke, D., Ferrin, T., and Giacomini, K. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Molecular Pharmacology, 65:512-9, 2004.
Gysin, S., Lee, S. H., Dean, N. M., and McMahon, M. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Research, 65:4870-80, 2005.
Gysin, S., Rickert, P., Kastury, K., and McMahon, M. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes, Chromosomes, and Cancer, 44:37-51, 2005.
Hager, J., Hodgson, J., Fridlyand, J., Hariono, S., Gray, J., and Hanahan, D. Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer Research, 64:2406-10, 2004.
Hebrok, M. Hedgehog signaling in pancreas development. Mechanisms of Development, 120:45-57, 2003.
Hebrok, M. and Reichardt, L.F. Brain meets pancreas: netrin, an axon guidance molecule, controls epithelial cell migration. Trends in Cell Biology, 14:153-5, 2004.
Heiser, P.W. and Hebrok, M. Development and cancer: lessons learned in the pancreas. Cell Cycle, 3:270-2, 2004.
Heiser, P. W., Lau, J., Taketo, M. M., Herrera, P. L., and Hebrok, M. Stabilization of beta-catenin impacts pancreas growth. Development, 133:2023-32, 2006.
Hodgson, G., Hager, J. H., Volik, S., Hariono, S., Wernick, M., Moore, D., Nowak, N., Albertson, D. G., Pinkel, D., Collins, C., Hanahan, D., and Gray, J. W. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet., 29:459-464, 2001.
Holly, E. A., Eberle, C. A., and Bracci, P. M. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. American Journal of Epidemiology, 158:432-41, 2003.
Hruban, R. H., Rustgi, A. K., Brentnall, T. A., Tempero, M. A., Wright, C. V., and Tuveson, D. A. Pancreatic Cancer in Mice and Man: The Penn Workshop 2004. Cancer Research, 66:14-70, 2006.
Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F. Y., Greenbaum, D. C., Hager, J. H., Bogyo, M., and Hanahan, D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell, 5:443-53, 2004.
Joyce, J. A., Freeman, C., Meyer-Morse, N., Parish, C. R., and Hanahan, D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene, 24:4037-51, 2005.
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., and Hanahan, D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4:393-403, 2003.
Kawahira, H., Ma, N. H., Tzanakakis, E. S., McMahon, A. P., Chuang, P. T., and Hebrok, M. Combined activities of hedgehog signaling inhibitors regulate pancreas development. Development, 130:4871-9, 2003.
Kawahira, H., Scheel, D. W., Smith, S. B., German, M. S., and Hebrok, M. Hedgehog signaling regulates expansion of pancreatic epithelial cells. Developmental Biology, 280:111-21, 2005.
Kern, S., Hruban, R., Hollingsworth, M. A., Brand, R., Adrian, T.E., Jaffee, E., and Tempero, M. A. White paper: the product of a pancreas cancer think tank. Cancer Research, 61:4923-32, 2001.
Ko, A. H., Dito, E., Schillinger, B., Venook, A. P., Bergsland, E. K., and Tempero, M. A. Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Oncology, 2006.
Ko, A.H., Quivey, J., Venook A., Bergsland, E., Dito, E., Schillinger, B., Tempero, M.A. A phase II study of fixed-dose rate gemcitabine plus low dose cisplatin following consolidative chemoradiation for locally advanced pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics, in press.
Ko, A. H., Hwang, J., Venook, A. P., Abbruzzese, J., Bergsland, E. K., and Tempero, M. A. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. British Journal of Cancer, 93:195-9, 2005.
Korn, W. M., Macal, M., Christian, C., Lacher, M. D., McMillan, A., Rauen, K. A., Warren, R. S., and Ferrell, L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Therapy, 13:792-797, 2006.
Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch T. J., Zhu, A. X., Meyerhardt, J. A., Heymach, J. V., Fogler, W. E., Sidor, C., Michelini, A., Kinsella, K., Venook, A. P., and Fuchs, C. S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 24:3555-61, 2006.
Lacher, M. D., Tiirikainen, M. I., Saunier, E. F., Christian, C., Anders, M., Oft, M., Balmain, A., Akhurst, R. J., and Korn, W. M. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Research, 66:1648-1657, 2006.
Lau, J., Kawahira, H., and Hebrok, M. Hedgehog signaling in pancreas development and disease. Cellular and Molecular Life Sciences, 63:642-52, 2006.
Lawlor, E. R., Soucek, L., Brown-Swigart, L., Shchors, K., Bialucha, C. U., and Evan, G. I. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Research, 66:4591-601, 2006.
Leabman, M., Huang, C., Kawamoto, M., Johns, S., Stryke, D., Ferrin, T., DeYoung, J., Taylor, T., Clark, A., Herskowitz, I., and Giacomini, K. Pharmacogenetics of Membrane Transporters Investigators. Polymorphisms in a human kidney xenobiotic transpoter, OCT2, exhibit altered function. Pharmacogenetics, 12:395-405, 2002.
Lopez, T. and Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 1:339-53, 2002.
Osato, D., Huang, C., Kawamoto, M., Johns, S., Stryke, D., Wang, J., Ferrin, T., Herskowitz, I., and Giacomini, K. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics, 13:297-301, 2003.
Owen, R., Badagnani, I., and Giacomini, K. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem, 2006.
Owen, R., Gray, J., Taylor, T., Carlson, E., Huang, C., Kawamoto, M., Johns, S., Stryke, D., Ferrin, T., and Giacomini, K. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics, 15:83-90, 2005.
Owen, R., Lagpacan, L., Taylor, T., De La Cruz, M., Huang, C., Kawamoto, M., Johns, S., Stryke, D., Ferrin, T., and Giacomini, K. Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab Dispos, 34:12-5, 2006.
Patil, M., Zhang, J., Ho, C., Cheung, S., Fan, S., and Chen, X. Hedgehog signaling in human hepatocellular carcinoma. Cancer Biology and Therapy, 5:111-7, 2006.
Pelengaris, S., Khan, M., and Evan, G. I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 109:321-34, 2002.
Perez, S. E., Cano, D. A., Dao-Pick, T., Rougier, J. P., Werb, Z., and Hebrok, M. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes, 54:694-701, 2005.
Pietras, K., and Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Journal of Clinical Oncology, 23:939-52, 2005.
Ries, S. J., Brands, C. H. Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., and Korn, W. M. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med, 10:1128-1133, 2000.
Rutter, J. L., Bromley, C. M., Goldstein, A. M., Elder, D. E., Holly, E. A., Guerry, D. T., Hartge, P., Struewing, J. P., Hogg, D., Halpern, A., Sagebiel, R. W., and Tucker, M. A. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer, 101:2809-16, 2004.
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L., and Evan, G. I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1 beta. Genes Dev., 20:2527-38, 2006.
Shum, Y., Leabman, M., Feng, B., Mangravite, L., Huang, C., Stryke, D., Kawamoto, M., Johns, S., DeYoung, J., Carlson, E., Ferrin, T., Herskowitz, I., and Giacomini, K. Pharmacogenetics Of Membrane Transporters Investigators. Proc Natl Acad Sci USA, 100:5902-7, 2003.
Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., and Abbruzzese, J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. Journal of Clinical Oncology, 21:3402-8, 2003.
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V., Antoniu, B., McMahon, M., Warshaw, A. L., and Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425:851-6, 2003.
Urban, T., Sebro, R., Hurowitz, E., Leabman, M., Badagnani, I., Lagpacan, L., Risch, N., and Giacomini, K. Functional genomics of membrane transporters in human populations. Genome Research, 16:223-30, 2006.
Wang, F., Gupta, S., and Holly, E. A. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco bay area, California. Cancer Epidemiology Biomarkers and Prevention, 15:1458-63, 2006.
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., Lippard S. J., and Giacomini, K. M. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Research, in press, 2006.
